# Final Review

**Purpose:** Log the paper's final state after all revisions
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-29T22:10:31.436908
**Response ID:** resp_0c8156c07ea9d67000697bcbf317788193a8ce498026969697
**Tokens:** 41438 in / 6840 out
**Response SHA256:** 9dbbc58b53d72435

---

## Referee Report (Top General-Interest Journal Standard)

### Summary / main message
This paper estimates the effect of *must-access* PDMP mandates on state labor market aggregates (log employment; unemployment rate) using staggered adoption DiD, primarily Callaway–Sant’Anna (2021) with not-yet-treated controls, 2007–2023 LAUS data. The headline result is a precise null: roughly +0.004 log points for employment and −0.24 pp for unemployment (both insignificant). The paper is careful about staggered DiD pitfalls and clearly explains why never-treated controls are thin (KS, MO, NE, SD).

At a methodological level, the paper largely “clears the bar” (proper staggered DiD; standard errors; event studies; sensitivity analysis). However, at an AER/QJE/JPE/ReStud/Ecta bar, the paper is not yet close. The biggest issues are (i) **outcome choice and aggregation** (log employment levels are dominated by population growth and macro shocks; the estimand is not tightly linked to opioid mechanisms), (ii) **identification credibility vs. adoption endogeneity and regional shocks** (coal/energy, Great Plains controls, COVID timing), (iii) **internal inconsistencies in data construction** (March snapshot vs annual averages) and (iv) **limited novelty/insight relative to existing work** given the aggregate-null design and the acknowledged dilution problem. The paper reads as a competent policy-eval report; top journals will demand a sharper estimand, stronger design, and richer mechanisms/heterogeneity.

Below I give a rigorous, demanding set of comments.

---

# 1. FORMAT CHECK

### Length
- The PDF excerpt runs to roughly **67 pages including appendices** (page numbers visible through the appendix). The **main text appears ~40 pages** (through References/Appendix start around p. 44). This comfortably exceeds the 25-page minimum.
- For a top journal, the opposite issue arises: the main text is long and could be tightened substantially once the design is improved.

### References
- The bibliography is substantial and includes the key staggered DiD methodology papers (Callaway–Sant’Anna 2021; Sun–Abraham 2021; de Chaisemartin–D’Haultfœuille 2020; Goodman-Bacon 2021; Borusyak–Jaravel–Spiess 2024; Rambachan–Roth 2023; Roth et al. 2023) and core PDMP papers (Buchmueller–Carey 2018; Dave et al. 2021; Patrick et al. 2016).
- **But** the policy/labor literature positioning is still incomplete (see Section 4 below). Also, several citations appear slightly off (e.g., “Horwitz et al. (2018)” in Table 2 notes vs Horwitz et al. 2021 elsewhere).

### Prose (bullets vs paragraphs)
- Introduction (pp. 3–5), institutional background (pp. 5–8), and discussion/conclusion (pp. 34–39) are written in paragraphs.
- Bullet lists appear in Data (variable definitions) and Threats/Robustness—acceptable. No “FAIL” here.

### Section depth
- Major sections generally have multiple substantive paragraphs (Intro, Background/Lit, Data, Empirical Strategy, Results, Discussion).
- Some subsections read like a checklist (especially Robustness, pp. 29–34). That’s fine for an appendix, but for the main text you should consolidate and prioritize.

### Figures
- Figures shown have axes and visible data (e.g., Figures 2–6 event studies; Figure 1 adoption timing). Titles/notes are present.
- **Quality issue:** event-study figures appear legible, but the adoption “lollipop” (Figure 1, p. 11) is crowded. For publication, you need a more readable design (group by cohort with counts; or a histogram of adoption years plus a map).

### Tables
- Tables contain real numbers and SEs (Tables 1–4 etc.). No placeholders.
- **Important inconsistency:** Table 1 notes say “annual averages of monthly BLS LAUS estimates,” while the text says you use **March monthly** values (Data section around pp. 8–9; Appendix A.1 repeats March). This is not a cosmetic issue; it affects interpretation and treatment-timing contamination.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- **PASS.** Main estimates report SEs (Table 3, p. ~20). Event-study tables report SEs and (sometimes) uniform CIs (Tables 7–8).

### (b) Significance testing
- **PASS.** p-values reported for main ATTs; stars in some tables; placebo tests (Table 20); bootstrap inference for CS.

### (c) Confidence intervals
- Mixed.
  - The abstract and text mention approximate 95% CIs for headline estimates (pp. 1–4).
  - But **Table 3 (main results)** does **not** report 95% CIs. Top journals typically expect CIs in the main table or in a clearly referenced companion table.
  - Event studies provide uniform bands (good practice).

### (d) Sample sizes
- **PASS** for main regressions: N=850 and number of states are shown in Table 3. Robustness tables mostly report N.

### (e) DiD with staggered adoption
- **PASS** in principle: primary estimator is Callaway–Sant’Anna with not-yet-treated controls and anticipation window.
- However, there are still **design weaknesses**:
  1. **Thin never-treated group** is correctly diagnosed (pp. 15–17; 29–31), but you still present a lot of heterogeneity analysis using never-treated controls (Table 4) despite arguing those comparisons are problematic.
  2. Your CS event-study Table 7 shows some pointwise significant pre-trends (e.g., e = −2 significant at **pointwise** level) but you argue pre-trends are “clean” under uniform bands. That’s defensible, but you should be more disciplined: stop starring coefficients that you explicitly say should be judged under simultaneous inference.

### (f) RDD criteria
- Not applicable (no RDD).

**Bottom line on methodology:** Inference and staggered DiD implementation are mostly competent. The paper is not unpublishable on “statistical inference” grounds. The larger concern is whether the estimand/design can answer the substantive question in a way that meets top-journal standards.

---

# 3. IDENTIFICATION STRATEGY

### Credibility
The identification claim is: conditional parallel trends for not-yet-treated controls (CS-DiD), with anticipation=1 to address partial exposure in the transition year.

**Core problems:**

1. **Outcome choice is poorly aligned with mechanisms.**
   - You use **log total employment** (LAUS). Employment *levels* primarily capture population size, long-run demographic changes, and macro cycles—only weakly tied to opioid policy mechanisms.
   - The paper acknowledges dilution (Discussion, pp. 34–36), but then the entire empirical design is built around an outcome where dilution is essentially guaranteed. A top journal will ask: *why is this the right outcome/level of aggregation?*

2. **Treatment timing/adoption is plausibly endogenous to opioid severity and economic structure.**
   - Early adopters (WV/KY/NM) were hit hard by opioids *and* had large contemporaneous sectoral shocks (coal/energy). You note cohort heterogeneity (Table 4) and even flag coal-industry decline as confounding (pp. 26–28), but you do not seriously model it.
   - The paper needs an identification strategy that is robust to **region×year** or **industry-shock** confounding, or else it should avoid interpreting cohort-level differences at all.

3. **Near-universal adoption undermines clean counterfactual construction.**
   - You correctly motivate not-yet-treated controls. But not-yet-treated units are themselves on a trajectory toward treatment and may have **policy bundles** and **pre-trends** related to opioid crisis severity. You include some concurrent policies only in TWFE robustness (pp. 28–29), not within the CS framework (except one covariate-adjusted variant).

4. **COVID timing severely contaminates late cohorts.**
   - You do a pre-COVID subsample (Table 18), good. But the pandemic is not just “absorbed by year FE”; state responses were heterogeneous and correlated with politics, which is correlated with PDMP policy style. A top journal would expect a more careful treatment (drop 2020–2021 entirely; or use 2019 as last outcome year in the main spec and put COVID in appendix).

### Key assumptions discussed?
- Parallel trends and anticipation are discussed carefully (pp. 12–17).
- Event-study diagnostics are presented with simultaneous bands (good).
- HonestDiD sensitivity is a plus (pp. 32–33; Figure 8).

### Placebos / robustness
- You provide: placebo treatment timing (Table 20), leave-one-out, pre-COVID subsample, TWFE with controls, BJS imputation.
- **But robustness is not targeted at the main identification threats.** You need robustness to:
  - **state-specific macro shocks correlated with adoption** (coal/energy/Great Plains agriculture boom),
  - **population scaling** (employment levels vs rates),
  - **heterogeneous timing and partial exposure** (monthly outcome and exact effective dates).

### Do conclusions follow?
- The conclusion “no detectable effect on state employment aggregates” is supported for *that specific outcome*.
- But the paper repeatedly gestures at broader welfare/policy interpretations (“does not reverse labor market damage,” “policy implications,” pp. 37–39) that are **not warranted** given the dilution and mismatch between outcomes and opioid harms.

### Limitations discussed?
- Yes, and credibly (pp. 36–37). However, stating the limitation (“aggregate dilution”) is not enough—top journals expect you to **solve** it or pivot to outcomes where the limitation is not fatal.

---

# 4. LITERATURE (missing references + BibTeX)

### DiD / panel event study methodology
You cite many of the right papers, but several highly relevant pieces that top journals commonly expect are missing or underused:

1. **Goldsmith-Pinkham, Sorkin, Swift (2022)** — diagnostic and interpretation of TWFE/event-study weights; complements Goodman-Bacon and is widely cited in applied work.
```bibtex
@article{GoldsmithPinkhamSorkinSwift2022,
  author  = {Goldsmith-Pinkham, Paul and Sorkin, Isaac and Swift, Henry},
  title   = {Bacon Decomposition for Difference-in-Differences with Variation in Treatment Timing},
  journal = {Journal of Econometrics},
  year    = {2022},
  volume  = {??},
  pages   = {??--??}
}
```
(*Fill in vol/pages correctly; the title/year are commonly cited but you must verify exact bibliographic details.*)

2. **Wooldridge (2021) / (2023) on two-way FE and DiD** — widely used reference for practitioners; helps justify estimands and standard error choices.
```bibtex
@article{Wooldridge2021,
  author  = {Wooldridge, Jeffrey M.},
  title   = {Two-Way Fixed Effects, the Two-Way Mundlak Regression, and Difference-in-Differences Estimators},
  journal = {Working Paper},
  year    = {2021}
}
```
(If you cite this, cite the final published version if available by now; otherwise label as WP.)

3. **Conley and Taber (2011)** — inference when the number of treated/control groups is small. This is directly relevant because your never-treated group is 4 states.
```bibtex
@article{ConleyTaber2011,
  author  = {Conley, Timothy G. and Taber, Christopher R.},
  title   = {Inference with Difference in Differences with a Small Number of Policy Changes},
  journal = {Review of Economics and Statistics},
  year    = {2011},
  volume  = {93},
  number  = {1},
  pages   = {113--125}
}
```

### PDMP / opioid policy literature
Your PDMP citations are decent, but you are missing key economics/health-econ papers that a referee will expect:

4. **Pardo (2017)** — PDMPs and opioid outcomes; widely cited early causal evidence.
```bibtex
@article{Pardo2017,
  author  = {Pardo, Bryce},
  title   = {Do More Robust Prescription Drug Monitoring Programs Reduce Prescription Opioid Overdose?},
  journal = {Addiction},
  year    = {2017},
  volume  = {112},
  number  = {10},
  pages   = {1773--1783}
}
```

5. **Alpert, Powell, Pacula (2018)** you have; but you should connect more explicitly to the **policy substitution** literature and cite additional work on transitions to illicit markets post-supply restrictions (verify best fits; examples below).

6. **Pain and labor supply / disability channel** (highly relevant to your mechanism discussion):
- There is a substantial literature connecting pain, disability, and labor supply; your Discussion cites Autor–Duggan (2003) and Krueger (2017) but does not engage the pain/disability labor literature in a serious way. At minimum, add a citation on pain and labor outcomes and explain why your aggregate employment outcome should move.

*(I am not adding BibTeX here because the best canonical choice depends on what you actually use; but you should add at least one strong peer-reviewed reference on pain and labor supply and one on disability insurance participation and labor force exit in the 2000s–2010s.)*

### Contribution positioning
Right now the paper’s claim to novelty is: “first CS-DiD on must-access PDMP mandates and state employment aggregates with long window” (pp. 4–5). That is unlikely to satisfy a top general-interest journal unless you:
- either find a clearly interpretable and important effect,
- or develop a methodological contribution about near-universal adoption designs beyond a brief “thin control group” discussion.

As written, the paper is best framed as a careful null in a policy space—valuable, but typically more suitable for a field journal unless the design and outcomes are substantially strengthened.

---

# 5. WRITING QUALITY (CRITICAL)

### (a) Prose vs bullets
- Major sections are paragraph-based; acceptable.
- However, the paper reads more like a **technical report** than a top-journal article. There is too much “method inventory” and not enough “economic argument.”

### (b) Narrative flow
- The Introduction asks a good question and motivates the chain from prescribing to labor markets (pp. 3–4).
- But the narrative weakens because the outcome choice (state employment level) is not defended as the economically relevant margin. A top-journal reader will quickly conclude: “This outcome cannot plausibly move; of course it’s null.”

### (c) Sentence quality
- Generally clear and professional, but often overlong and repetitive in robustness/limitations sections. Tighten.

### (d) Accessibility
- You explain CS-DiD and staggered adoption clearly (pp. 12–17).
- But you do not provide sufficient *economic* intuition for magnitudes: what is a plausible effect on employment **rates** among affected groups, and what does that imply for state aggregates? You do this partially via an MDE argument (p. ~20), but it reads like an afterthought and actually undermines the paper’s raison d’être.

### (e) Figures/Tables
- Tables are mostly self-explanatory.
- Event-study figures need to be more publication-ready (larger fonts; fewer horizons in main text; place extended horizons in appendix).
- Most importantly: resolve the **March vs annual average** inconsistency everywhere (main text, Table 1 notes, Appendix A.1). This is currently a credibility red flag.

---

# 6. CONSTRUCTIVE SUGGESTIONS (to make it publishable at a top outlet)

## A. Fix the outcome/estimand problem (highest priority)
1. **Replace log employment levels with rate-based outcomes that match mechanisms**:
   - Employment-to-population ratio (prime-age, overall).
   - Labor force participation rate.
   - Disability insurance recipiency / SSDI applications (if available).
   - Hours worked / earnings (CPS/ACS).
   - Sectoral employment in industries plausibly affected (construction, manufacturing, mining) if you have a mechanism.

2. **Use microdata** (CPS ASEC monthly basic, ACS) to:
   - focus on prime-age, non-college men, high-pain occupations, or groups with high opioid exposure.
   - implement CS-DiD at the individual level with state policies.
   - show heterogeneous effects where theory suggests they should be largest.

Without this pivot, the paper’s own dilution argument (pp. 34–36) implies the design is almost guaranteed to find “nothing.”

## B. Align timing with data (monthly panel)
- If you insist on LAUS, use **monthly LAUS** with exact effective dates. Then you can avoid the awkward “full-exposure year” coding and the anticipation window workarounds.
- Monthly data also lets you show whether there are short-run disruptions (clinic workflow frictions) vs medium-run adjustments.

## C. Strengthen identification against confounding shocks
1. Add **region×year** fixed effects (Census region-year) or state-specific exposure controls to major macro shocks (oil/coal price interactions with pre-period industry shares).
2. Incorporate **policy bundle controls inside CS-DiD** (you currently do this mainly in TWFE). CS supports covariates; implement them systematically, not as a one-off.
3. Pre-register (conceptually) a small set of primary specifications; right now the robustness garden is large and sometimes contradictory (e.g., covariate-adjusted CS becomes significant, Table 19).

## D. Make the “thin control group” point into a real contribution
If you want a general-interest journal angle, you could:
- formalize and quantify the bias/instability from tiny never-treated groups (e.g., show sensitivity to each never-treated state, and to alternative donor pools),
- compare CS not-yet-treated, synthetic DiD, matrix completion, interactive FE, and explicit extrapolation approaches,
- provide guidance for applied researchers in “near-universal adoption” settings.

Right now this is discussed but not developed enough to be a publishable methodological contribution.

## E. Clean up presentation and internal consistency
- Resolve the March vs annual-average contradiction everywhere.
- Stop using significance stars in event-study tables if you claim uniform bands are the correct inferential object; or provide both clearly.
- Move long robustness inventories to appendix; keep a crisp main narrative.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Uses modern staggered DiD estimators appropriately (CS-DiD with not-yet-treated controls; honest sensitivity; uniform bands).
- Transparent about near-universal adoption and the thin never-treated control problem.
- Clear writing at the econometric-method level; replication-style detail is good.

### Critical weaknesses
- **Primary outcome (log total employment) is not a credible margin** for detecting opioid-policy effects; it is dominated by population and macro trends and mechanically dilutes any plausible effects.
- Identification remains vulnerable to adoption endogeneity + sectoral/regional shocks; cohort heterogeneity results are not interpretable without stronger controls.
- The paper’s key limitation (aggregate dilution) is so strong that it threatens the paper’s substantive contribution.
- Internal inconsistency in data construction (March vs annual averages) undermines confidence.

### What would change my view
A revised paper that (i) uses outcomes plausibly affected (EPOP/LFP/disability; ideally microdata), (ii) uses timing consistent with policy effective dates (monthly or exact), and (iii) demonstrates heterogeneity consistent with mechanisms (larger effects where opioid exposure is high) could become a credible AEJ:EP paper. For AER/QJE/JPE/ReStud/Ecta, you likely need either a stronger design (e.g., quasi-random variation in mandate strength/enforcement) or a broader methodological contribution about near-universal adoption.

---

DECISION: REJECT AND RESUBMIT